Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
France Targets Shein, Temu With Fast-Fashion Fees 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Milei Threatens Falkland Oil Firms With Sanctions 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
OpenAI Nears Astra AI Model Launch With Safety Focus 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
BRIDGEWATER, N.J., March 06, 2018 -- Clinical Genomics, a leading provider of colorectal cancer testing and solutions, is pleased to announce that its CLIA licensed and CAP accredited New Jersey laboratory is now licensed by the Florida Agency for Healthcare Administration to offer services for patients residing within the state of Florida. Clinical Genomics is the sole provider of COLVERA™, a liquid biopsy ctDNA assay used to detect residual disease and recurrent disease in patients previously diagnosed with colorectal cancer.
Dr. Lawrence LaPointe, President and CEO of Clinical Genomics, said, “This approval allows Florida doctors to offer COLVERA to their patients in one of the largest US oncology markets.”
“We are pleased to make available our world-class liquid biopsy testing to colorectal cancer surgeons and medical oncologists for the nearly 10,000 patients in Florida who are treated for colorectal cancer each year,” added Dr. John P. Alsobrook II, DABCC, FACB, Laboratory Site Director and Vice President of Operations for Clinical Genomics Pathology.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, InSure® ONE™, a one sample FIT used to detect lower GI bleeding, and COLVERA™, a proprietary liquid biopsy blood test identifying circulating tumor DNA for detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.
Media Contact:
Patty Jenkins
[email protected]
+ 1.412.376. 2770
